ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

RLAY Relay Therapeutics Inc

7.98
0.71 (9.77%)
Jun 07 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,901,296
Bid Price 7.82
Ask Price 10.00
News -
Day High 8.01

Low
5.70

52 Week Range

High
13.32

Day Low 6.99
Share Name Share Symbol Market Stock Type
Relay Therapeutics Inc RLAY NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.71 9.77% 7.98 23:00:06
Open Price Low Price High Price Close Price Previous Close
7.08 6.99 8.01 7.90 7.27
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
14,664 1,901,296 US$ 7.53 US$ 14,325,579 - 5.70 - 13.32
Last Trade Type Quantity Price Currency
18:37:42 50 US$ 7.82 USD

Relay Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.04B 131.18M - 31.97M -341.97M -2.61 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Relay Therapeutics News

Date Time Source News Article
6/06/202407:00Edgar (US Regulatory)Form 8-K - Current report
6/06/202406:00GlobeNewswire Inc.Relay Therapeutics Discloses Three New Programs at New..
6/05/202419:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/05/202419:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/05/202419:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/05/202419:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/05/202415:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
6/05/202415:05GlobeNewswire Inc.Relay Therapeutics Announces Clinical Trial Collaboration..
6/04/202415:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
6/03/202415:05Edgar (US Regulatory)Form 8-K - Current report
5/21/202415:05GlobeNewswire Inc.Relay Therapeutics to Participate in Upcoming Investor..
5/13/202407:30GlobeNewswire Inc.Relay Therapeutics to Host New Program and Platform Event on..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RLAY Message Board. Create One! See More Posts on RLAY Message Board See More Message Board Posts

Historical RLAY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.328.016.216.971,393,2861.6626.27%
1 Month6.788.016.146.801,364,0051.2017.70%
3 Months8.058.715.706.941,311,009-0.07-0.87%
6 Months9.0612.145.708.461,160,897-1.08-11.92%
1 Year11.8013.325.709.081,140,314-3.82-32.37%
3 Years32.3038.6055.7017.051,047,633-24.32-75.29%
5 Years33.9864.375.7020.06926,030-26.00-76.52%

Relay Therapeutics Description

Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020.

Your Recent History

Delayed Upgrade Clock